How I manage Evans Syndrome and AIHA cases in children

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The management of Evans Syndrome in children is challenging due to the lack of evidence-based data on treatment. Steroids, the first-choice therapy, are successful in about 80% of cases. For children who are resistant, relapse or become steroid-dependent, rituximab is considered a valid second-line treatment, with the exception of those with an underlying diagnosis of autoimmune lymphoproliferative syndrome who may benefit from other options such as mycophenolate mofetil and sirolimus. Better knowledge of the immunological mechanisms underlying cytopenias and the availability of new immunosuppressive drugs can be helpful in the choice of more targeted therapies that would enable the reduction of the use of long-term steroid administration or other more aggressive options, such as splenectomy or stem cell transplantation. This manuscript provides an overview of the pathogenic background of the disease, and suggests a clinical approach to diagnosis and treatment with a particular focus on the management of relapsing/resistant disease.

Original languageEnglish
Pages (from-to)524-534
Number of pages11
JournalBritish Journal of Haematology
Volume172
Issue number4
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Steroids
Autoimmune Lymphoproliferative Syndrome
Mycophenolic Acid
Therapeutics
Stem Cell Transplantation
Splenectomy
Sirolimus
Immunosuppressive Agents
Evans Syndrome
Recurrence
Pharmaceutical Preparations
Rituximab

Keywords

  • Autoimmune haemolytic anaemia
  • Autoimmune lymphoproliferative syndrome
  • Children
  • Evans syndrome
  • Immune thrombocytopenia
  • Immunosuppression

ASJC Scopus subject areas

  • Hematology

Cite this

How I manage Evans Syndrome and AIHA cases in children. / Miano, Maurizio.

In: British Journal of Haematology, Vol. 172, No. 4, 01.02.2016, p. 524-534.

Research output: Contribution to journalArticle

@article{856c37a6925d452699cbb52c0d3f18cb,
title = "How I manage Evans Syndrome and AIHA cases in children",
abstract = "The management of Evans Syndrome in children is challenging due to the lack of evidence-based data on treatment. Steroids, the first-choice therapy, are successful in about 80{\%} of cases. For children who are resistant, relapse or become steroid-dependent, rituximab is considered a valid second-line treatment, with the exception of those with an underlying diagnosis of autoimmune lymphoproliferative syndrome who may benefit from other options such as mycophenolate mofetil and sirolimus. Better knowledge of the immunological mechanisms underlying cytopenias and the availability of new immunosuppressive drugs can be helpful in the choice of more targeted therapies that would enable the reduction of the use of long-term steroid administration or other more aggressive options, such as splenectomy or stem cell transplantation. This manuscript provides an overview of the pathogenic background of the disease, and suggests a clinical approach to diagnosis and treatment with a particular focus on the management of relapsing/resistant disease.",
keywords = "Autoimmune haemolytic anaemia, Autoimmune lymphoproliferative syndrome, Children, Evans syndrome, Immune thrombocytopenia, Immunosuppression",
author = "Maurizio Miano",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/bjh.13866",
language = "English",
volume = "172",
pages = "524--534",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "4",

}

TY - JOUR

T1 - How I manage Evans Syndrome and AIHA cases in children

AU - Miano, Maurizio

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The management of Evans Syndrome in children is challenging due to the lack of evidence-based data on treatment. Steroids, the first-choice therapy, are successful in about 80% of cases. For children who are resistant, relapse or become steroid-dependent, rituximab is considered a valid second-line treatment, with the exception of those with an underlying diagnosis of autoimmune lymphoproliferative syndrome who may benefit from other options such as mycophenolate mofetil and sirolimus. Better knowledge of the immunological mechanisms underlying cytopenias and the availability of new immunosuppressive drugs can be helpful in the choice of more targeted therapies that would enable the reduction of the use of long-term steroid administration or other more aggressive options, such as splenectomy or stem cell transplantation. This manuscript provides an overview of the pathogenic background of the disease, and suggests a clinical approach to diagnosis and treatment with a particular focus on the management of relapsing/resistant disease.

AB - The management of Evans Syndrome in children is challenging due to the lack of evidence-based data on treatment. Steroids, the first-choice therapy, are successful in about 80% of cases. For children who are resistant, relapse or become steroid-dependent, rituximab is considered a valid second-line treatment, with the exception of those with an underlying diagnosis of autoimmune lymphoproliferative syndrome who may benefit from other options such as mycophenolate mofetil and sirolimus. Better knowledge of the immunological mechanisms underlying cytopenias and the availability of new immunosuppressive drugs can be helpful in the choice of more targeted therapies that would enable the reduction of the use of long-term steroid administration or other more aggressive options, such as splenectomy or stem cell transplantation. This manuscript provides an overview of the pathogenic background of the disease, and suggests a clinical approach to diagnosis and treatment with a particular focus on the management of relapsing/resistant disease.

KW - Autoimmune haemolytic anaemia

KW - Autoimmune lymphoproliferative syndrome

KW - Children

KW - Evans syndrome

KW - Immune thrombocytopenia

KW - Immunosuppression

UR - http://www.scopus.com/inward/record.url?scp=84957069964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957069964&partnerID=8YFLogxK

U2 - 10.1111/bjh.13866

DO - 10.1111/bjh.13866

M3 - Article

C2 - 26625877

AN - SCOPUS:84957069964

VL - 172

SP - 524

EP - 534

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -